Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Investigating the Effectiveness of Calisda, a Digital Health Intervention for Patients With Menopause Symptoms (CHIME)

12 november 2026 uppdaterad av: Gaia AG

Investigating the Effectiveness of Calisda, a Digital Health Intervention for Patients With Menopause Symptoms: Randomized Controlled Trial (CHIME Trial)

The goal of this clinical trial is to find out if calisda, a digital health intervention, can help women with menopause symptoms manage their symptoms and improve their quality of life.

The main questions it aims to answer are:

  • Does calisda, together with regular treatment, improve health outcomes after six months better than regular treatment alone?
  • Are the positive effects of calisda already noticeable after three months?

Researchers will compare two groups:

  • Intervention group: Participants use the calisda intervention and continue their usual treatment.
  • Control group: Participants continue with their usual treatment only.

Participants will:

  • Fill out questionnaires online at the start of the study, after 3 months, and after 6 months
  • Continue with their usual treatment (both groups) and use calisda, a digital health intervention, for six months (intervention group only)

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Intervention / Behandling

Detaljerad beskrivning

This pragmatic, two-arm randomized controlled trial evaluates the effectiveness of calisda, a certified medical device (CE-marked, risk class I), when used alongside regular treatment. The study compares the addition of this digital health intervention to treatment as usual (TAU) against TAU alone. Designed as an interactive online program, calisda incorporates recognized elements of cognitive behavioral therapy (CBT), behavior change, and patient education.

After confirming eligibility, participants are randomly assigned to one of two groups. The intervention group receives immediate access to calisda for six months alongside their usual treatment. The control group continues their regular treatment and is granted access to the intervention after a six-month waiting period.

Data is collected from both groups via online questionnaires at the start of the study, after three months, and after six months. The primary evaluation of effectiveness will be conducted at the six-month follow-up. Data collected at the three-month mark will be utilized to assess early treatment response.

Studietyp

Interventionell

Inskrivning (Beräknad)

388

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

40 år till 65 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Beskrivning

Inclusion Criteria:

  • Female biological sex
  • Age 40-65 years
  • Diagnosis of menopause symptoms (ICD-10 code: N95.1) confirmed by a medical document
  • Increased levels of menopause symptoms (MRS-II total score ≥ 14)
  • Reduced menopause-specific quality of life (MENQOL total score ≥ 3)
  • Stable symptom-related treatment (medication, psychotherapy, no treatment, …) for at least 60 days at the time of inclusion
  • Sufficient knowledge of the German language
  • Basic computer skills required for independent use of a digital intervention
  • Consent to participation

Exclusion Criteria:

  • Plans to change symptom-related treatment (medication, psychotherapy, …) in the upcoming 6 months after inclusion
  • Current or history of any malignancy except for basal and squamous cell skin tumors
  • Current HRT use
  • Premature, medically induced menopause (e.g. following bilateral oophorectomy)
  • Known somatic or psychiatric condition that might interfere with successful study participation (e.g. unstable neurologic or psychiatric disorder)
  • Previous use of a digital intervention for menopause symptoms (including calisda) or another digital intervention developed by GAIA.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: calisda

Participants will receive access to the digital health intervention calisda in addition to TAU.

Participants allocated to the intervention group will receive access to calisda in addition to treatment as usual (TAU).

calisda is a digital health intervention designed for women with menopause symptoms, accessible through a web browser. The program focuses on treatment methods derived from cognitive behavioral therapy (CBT), health behavior change, and patient education. Topics addressed by calisda include understanding menopausal changes and symptoms, coping with hot flashes and night sweats, sleep, mood, self-acceptance and self-worth, relationship communication, as well as information on hormone therapy and complementary approaches.

The program operates through interactive "dialogues", which are accompanied by illustrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their progress. Once registered, the program remains accessible for six months.

Inget ingripande: Control group

Participants allocated to the control group will receive access to treatment as usual (TAU).

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
29-item Menopause-Specific Quality of Life Questionnaire (MENQOL; 1-week recall) total score
Tidsram: 6 months

The MENQOL is a patient-reported outcome measure (PROM) with 29 items. Each item uses a two-stage response format. This questionnaire consists of four domains, with varying item numbers: "vasomotor", "psychosocial", "physical" and "sexual". To obtain the total score, the mean of the domain scores is computed. Both the domain and the total scores range from 1 to 8. Higher total scores indicate greater impairment of quality of life.

6 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Hot Flash Related Daily Interference Scale (HFRDIS) total score
Tidsram: 6 months

The HFRDIS is a 10-item PROM assessing the extent to which hot flashes interfere with daily activities and overall quality of life over the past week. Each item is rated from 0 ("did not interfere") to 10 ("completely interfere"). The total score is the mean of all items and ranges from 0 to 10. Higher total scores indicate greater hot flash interference and thus a worse outcome, whereas lower scores indicate less interference and a better outcome.

6 months
Insomnia Severity Index (ISI) total score
Tidsram: 6 months

The ISI is a 7-item PROM assessing the nature, severity, and impact of insomnia. Each item is rated on a 5-point scale from 0 to 4. The total score is the sum of all items and ranges from 0 to 28. Higher total scores indicate greater insomnia severity and thus a worse outcome, whereas lower scores indicate less insomnia severity and a better outcome.

6 months
Patient Health Questionnaire (PHQ-9) total score
Tidsram: 6 months

The PHQ-9 is a 9-item PROM assessing the severity of depressive symptoms. Each item is scored from 0 ("not at all") to 3 ("nearly every day"). The total score is the sum of all items and ranges from 0 to 27. Higher total scores indicate greater depressive symptom severity and thus a worse outcome, whereas lower scores indicate less severity and a better outcome.

6 months
Menopause Rating Scale II (MRS-II) total score
Tidsram: 6 months

The MRS-II is an 11-item PROM assessing the severity of menopause-related symptoms. Each item is rated from 0 ("no complaints") to 4 ("very severe symptoms"). The total score is the sum of all items and ranges from 0 to 44. Higher total scores indicate greater symptom severity and thus a worse outcome, whereas lower scores indicate less severity and a better outcome.

6 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Huvudutredare: Philipp Klein, Prof. Dr. med., Universität zu Lübeck, Zentrum für Integrative Psychiatrie ZiP gGmbH

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 november 2026

Primärt slutförande (Beräknad)

1 december 2027

Avslutad studie (Beräknad)

1 december 2027

Studieregistreringsdatum

Först inskickad

12 november 2026

Först inskickad som uppfyllde QC-kriterierna

12 november 2026

Första postat (Faktisk)

18 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

12 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • calisda RCT 2026

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera